{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:55:10Z","timestamp":1788418510911,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T00:00:00Z","timestamp":1660348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T00:00:00Z","timestamp":1660348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100017723","name":"Innovent Biologics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010881","name":"Suzhou Municipal Science and Technology Bureau","doi-asserted-by":"publisher","award":["SLJ202011"],"award-info":[{"award-number":["SLJ202011"]}],"id":[{"id":"10.13039\/501100010881","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010881","name":"Suzhou Municipal Science and Technology Bureau","doi-asserted-by":"publisher","award":["SLJ202011"],"award-info":[{"award-number":["SLJ202011"]}],"id":[{"id":"10.13039\/501100010881","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017962","name":"Jiangsu Commission of Health","doi-asserted-by":"publisher","award":["M2020043"],"award-info":[{"award-number":["M2020043"]}],"id":[{"id":"10.13039\/100017962","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017962","name":"Jiangsu Commission of Health","doi-asserted-by":"publisher","award":["M2020043"],"award-info":[{"award-number":["M2020043"]}],"id":[{"id":"10.13039\/100017962","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Special Technical Project of Diagnosis and Treatment of Key Clinical Diseases of Suzhou","award":["LCZX201813"],"award-info":[{"award-number":["LCZX201813"]}]},{"name":"Special Technical Project of Diagnosis and Treatment of Key Clinical Diseases of Suzhou","award":["LCZX201813"],"award-info":[{"award-number":["LCZX201813"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s00262-022-03267-5","type":"journal-article","created":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T17:02:36Z","timestamp":1660410156000},"page":"493-507","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Characterization of anti-CD79b\/CD3 bispecific antibody, a potential therapy for B cell malignancies"],"prefix":"10.1007","volume":"72","author":[{"given":"Jie","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaijie","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fufan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninghuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenggen","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihai","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuaixiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dian","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochao","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqiu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingliang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,13]]},"reference":[{"key":"3267_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer statistics, 2021. CA Cancer J Clin 71:7\u201333. https:\/\/doi.org\/10.3322\/caac.21654","journal-title":"CA Cancer J Clin"},{"key":"3267_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66:115\u2013132. https:\/\/doi.org\/10.3322\/caac.21338","journal-title":"CA Cancer J Clin"},{"key":"3267_CR3","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2005.1.321","author":"M Ghielmini","year":"2005","unstructured":"Ghielmini M (2005) Multimodality therapies and optimal schedule of antibodies: rituximab in lymphoma as an example. Hematol Am Soc Hematol Educ Program. https:\/\/doi.org\/10.1182\/asheducation-2005.1.321","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"3267_CR4","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/S0140-6736(12)60605-9","volume":"380","author":"KR Shankland","year":"2012","unstructured":"Shankland KR, Armitage JO, Hancock BW (2012) Non-Hodgkin lymphoma. Lancet 380:848\u2013857. https:\/\/doi.org\/10.1016\/S0140-6736(12)60605-9","journal-title":"Lancet"},{"key":"3267_CR5","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL et al (2015) Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national lymphocare study. J Clin Oncol 33:2516\u20132522. https:\/\/doi.org\/10.1200\/JCO.2014.59.7534","journal-title":"J Clin Oncol"},{"key":"3267_CR6","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N et al (2010) Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28:4184\u20134190. https:\/\/doi.org\/10.1200\/JCO.2010.28.1618","journal-title":"J Clin Oncol"},{"key":"3267_CR7","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/s0952-7915(00)00215-6","volume":"13","author":"L Matsuuchi","year":"2001","unstructured":"Matsuuchi L, Gold MR (2001) New views of BCR structure and organization. Curr Opin Immunol 13:270\u2013277. https:\/\/doi.org\/10.1016\/s0952-7915(00)00215-6","journal-title":"Curr Opin Immunol"},{"key":"3267_CR8","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/00129039-200106000-00001","volume":"9","author":"PG Chu","year":"2001","unstructured":"Chu PG, Arber DA (2001) CD79: a review. Appl Immunohistochem Mol Morphol 9:97\u2013106. https:\/\/doi.org\/10.1097\/00129039-200106000-00001","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"3267_CR9","first-page":"1966","volume":"10","author":"AP Zomas","year":"1996","unstructured":"Zomas AP, Matutes E, Morilla R, Owusu-Ankomah K, Seon BK, Catovsky D (1996) Expression of the immunoglobulin-associated protein B29 in B cell disorders with the monoclonal antibody SN8 (CD79b). Leukemia 10:1966\u20131970","journal-title":"Leukemia"},{"key":"3267_CR10","first-page":"413","volume":"84","author":"E Cabezudo","year":"1999","unstructured":"Cabezudo E, Carrara P, Morilla R, Matutes E (1999) Quantitative analysis of CD79b, CD5 and CD19 in mature B-cell lymphoproliferative disorders. Haematologica 84:413\u2013418","journal-title":"Haematologica"},{"key":"3267_CR11","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1182\/blood-2009-02-205500","volume":"114","author":"D Dornan","year":"2009","unstructured":"Dornan D, Bennett F, Chen Y et al (2009) Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood 114:2721\u20132729. https:\/\/doi.org\/10.1182\/blood-2009-02-205500","journal-title":"Blood"},{"key":"3267_CR12","doi-asserted-by":"publisher","first-page":"7046","DOI":"10.1158\/1078-0432.CCR-19-1337","volume":"25","author":"M Ormhoj","year":"2019","unstructured":"Ormhoj M, Scarfo I, Cabral ML et al (2019) Chimeric antigen receptor T cells targeting CD79b show efficacy in lymphoma with or without cotargeting CD19. Clin Cancer Res 25:7046\u20137057. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1337","journal-title":"Clin Cancer Res"},{"key":"3267_CR13","doi-asserted-by":"publisher","unstructured":"Sun LL, Ellerman D, Mathieu M et al (2015) Anti-CD20\/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies. Sci Transl Med 7:287ra70. https:\/\/doi.org\/10.1126\/scitranslmed.aaa4802","DOI":"10.1126\/scitranslmed.aaa4802"},{"key":"3267_CR14","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1182\/blood.2019003342","volume":"135","author":"K Pillarisetti","year":"2020","unstructured":"Pillarisetti K, Edavettal S, Mendonca M et al (2020) A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Blood 135:1232\u20131243. https:\/\/doi.org\/10.1182\/blood.2019003342","journal-title":"Blood"},{"key":"3267_CR15","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.molimm.2005.03.007","volume":"43","author":"S Offner","year":"2006","unstructured":"Offner S, Hofmeister R, Romaniuk A, Kufer P, Baeuerle PA (2006) Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol 43:763\u2013771. https:\/\/doi.org\/10.1016\/j.molimm.2005.03.007","journal-title":"Mol Immunol"},{"key":"3267_CR16","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1158\/0008-5472.CAN-13-3622-T","volume":"74","author":"TT Junttila","year":"2014","unstructured":"Junttila TT, Li J, Johnston J et al (2014) Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells. Cancer Res 74:5561\u20135571. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-3622-T","journal-title":"Cancer Res"},{"key":"3267_CR17","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","volume":"99","author":"Y Zhang","year":"2010","unstructured":"Zhang Y, Huo M, Zhou J, Xie S (2010) PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed 99:306\u2013314. https:\/\/doi.org\/10.1016\/j.cmpb.2010.01.007","journal-title":"Comput Methods Programs Biomed"},{"key":"3267_CR18","doi-asserted-by":"publisher","first-page":"12161","DOI":"10.1128\/JVI.75.24.12161-12168.2001","volume":"75","author":"M Hezareh","year":"2001","unstructured":"Hezareh M, Hessell AJ, Jensen RC, van de Winkel JG, Parren PW (2001) Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J Virol 75:12161\u201312168. https:\/\/doi.org\/10.1128\/JVI.75.24.12161-12168.2001","journal-title":"J Virol"},{"key":"3267_CR19","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1182\/blood-2007-01-066704","volume":"110","author":"AG Polson","year":"2007","unstructured":"Polson AG, Yu SF, Elkins K et al (2007) Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. Blood 110:616\u2013623. https:\/\/doi.org\/10.1182\/blood-2007-01-066704","journal-title":"Blood"},{"key":"3267_CR20","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1002\/eji.200636447","volume":"36","author":"A Caballero","year":"2006","unstructured":"Caballero A, Katkere B, Wen XY, Drake L, Nashar TO, Drake JR (2006) Functional and structural requirements for the internalization of distinct BCR-ligand complexes. Eur J Immunol 36:3131\u20133145. https:\/\/doi.org\/10.1002\/eji.200636447","journal-title":"Eur J Immunol"},{"key":"3267_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.102625","volume":"52","author":"PJ Engelberts","year":"2020","unstructured":"Engelberts PJ, Hiemstra IH, de Jong B et al (2020) DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine 52:102625. https:\/\/doi.org\/10.1016\/j.ebiom.2019.102625","journal-title":"EBioMedicine"},{"key":"3267_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2019.114657","volume":"379","author":"Y Iwata","year":"2019","unstructured":"Iwata Y, Sasaki M, Harada A et al (2019) Daily ascending dosing in cynomolgus monkeys to mitigate cytokine release syndrome induced by ERY22, surrogate for T-cell redirecting bispecific antibody ERY974 for cancer immunotherapy. Toxicol Appl Pharmacol 379:114657. https:\/\/doi.org\/10.1016\/j.taap.2019.114657","journal-title":"Toxicol Appl Pharmacol"},{"key":"3267_CR23","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL et al (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377:2531\u20132544. https:\/\/doi.org\/10.1056\/NEJMoa1707447","journal-title":"N Engl J Med"},{"key":"3267_CR24","doi-asserted-by":"publisher","DOI":"10.15252\/embj.201797980","author":"X He","year":"2018","unstructured":"He X, Klasener K, Iype JM, Becker M, Maity PC, Cavallari M, Nielsen PJ, Yang J, Reth M (2018) Continuous signaling of CD79b and CD19 is required for the fitness of Burkitt lymphoma B cells. EMBO J. https:\/\/doi.org\/10.15252\/embj.201797980","journal-title":"EMBO J"},{"key":"3267_CR25","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/gene.2009.70","volume":"10","author":"N Shulzhenko","year":"2009","unstructured":"Shulzhenko N, Morgun A, Matzinger P (2009) Spontaneous mutation in the Cd79b gene leads to a block in B-lymphocyte development at the C\u2019 (early pre-B) stage. Genes Immun 10:722\u2013726. https:\/\/doi.org\/10.1038\/gene.2009.70","journal-title":"Genes Immun"},{"key":"3267_CR26","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.3109\/10428194.2015.1113276","volume":"57","author":"JH Kim","year":"2016","unstructured":"Kim JH, Kim WS, Ryu K, Kim SJ, Park C (2016) CD79B limits response of diffuse large B cell lymphoma to ibrutinib. Leuk Lymphoma 57:1413\u20131422. https:\/\/doi.org\/10.3109\/10428194.2015.1113276","journal-title":"Leuk Lymphoma"},{"key":"3267_CR27","doi-asserted-by":"publisher","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","volume":"121","author":"DT Teachey","year":"2013","unstructured":"Teachey DT, Rheingold SR, Maude SL et al (2013) Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 121:5154\u20135157. https:\/\/doi.org\/10.1182\/blood-2013-02-485623","journal-title":"Blood"},{"key":"3267_CR28","doi-asserted-by":"publisher","first-page":"4542","DOI":"10.1182\/blood-2010-09-306449","volume":"117","author":"PA Moore","year":"2011","unstructured":"Moore PA, Zhang W, Rainey GJ et al (2011) Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood 117:4542\u20134551. https:\/\/doi.org\/10.1182\/blood-2010-09-306449","journal-title":"Blood"},{"key":"3267_CR29","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1158\/1535-7163.MCT-09-0369","volume":"8","author":"B Zheng","year":"2009","unstructured":"Zheng B, Fuji RN, Elkins K et al (2009) In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates. Mol Cancer Ther 8:2937\u20132946. https:\/\/doi.org\/10.1158\/1535-7163.MCT-09-0369","journal-title":"Mol Cancer Ther"},{"key":"3267_CR30","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1158\/0008-5472.CAN-19-1131","volume":"80","author":"M Klinger","year":"2020","unstructured":"Klinger M, Zugmaier G, Nagele V et al (2020) Adhesion of T cells to endothelial cells facilitates Blinatumomab-associated neurologic adverse events. Cancer Res 80:91\u2013101. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-1131","journal-title":"Cancer Res"},{"key":"3267_CR31","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133757","author":"K Staflin","year":"2020","unstructured":"Staflin K, Zuch de Zafra CL, Schutt LK et al (2020) Target arm affinities determine preclinical efficacy and safety of anti-HER2\/CD3 bispecific antibody. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.133757","journal-title":"JCI Insight"},{"key":"3267_CR32","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1158\/1078-0432.CCR-18-2752","volume":"25","author":"CL Zuch de Zafra","year":"2019","unstructured":"Zuch de Zafra CL, Fajardo F, Zhong W et al (2019) Targeting multiple myeloma with AMG 424, a novel anti-CD38\/CD3 bispecific T-cell-recruiting antibody optimized for cytotoxicity and cytokine release. Clin Cancer Res 25:3921\u20133933. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2752","journal-title":"Clin Cancer Res"},{"key":"3267_CR33","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1158\/1535-7163.MCT-17-0657","volume":"17","author":"D Mandikian","year":"2018","unstructured":"Mandikian D, Takahashi N, Lo AA et al (2018) Relative target affinities of T-cell-dependent bispecific antibodies determine biodistribution in a solid tumor mouse model. Mol Cancer Ther 17:776\u2013785. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0657","journal-title":"Mol Cancer Ther"},{"key":"3267_CR34","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00262-020-02679-5","volume":"70","author":"Y Wang","year":"2021","unstructured":"Wang Y, Ni H, Zhou S et al (2021) Tumor-selective blockade of CD47 signaling with a CD47\/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity. Cancer Immunol Immunother 70:365\u2013376. https:\/\/doi.org\/10.1007\/s00262-020-02679-5","journal-title":"Cancer Immunol Immunother"},{"key":"3267_CR35","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","volume":"18","author":"AF Labrijn","year":"2019","unstructured":"Labrijn AF, Janmaat ML, Reichert JM, Parren P (2019) Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov 18:585\u2013608. https:\/\/doi.org\/10.1038\/s41573-019-0028-1","journal-title":"Nat Rev Drug Discov"},{"key":"3267_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39:1\u201310. https:\/\/doi.org\/10.1016\/j.immuni.2013.07.012","journal-title":"Immunity"},{"key":"3267_CR37","doi-asserted-by":"publisher","first-page":"5258","DOI":"10.1158\/1078-0432.CCR-20-0926","volume":"26","author":"S Hipp","year":"2020","unstructured":"Hipp S, Voynov V, Drobits-Handl B, Giragossian C, Trapani F, Nixon AE, Scheer JM, Adam PJ (2020) A bispecific DLL3\/CD3 IgG-like T-cell engaging antibody induces antitumor responses in small cell lung cancer. Clin Cancer Res 26:5258\u20135268. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0926","journal-title":"Clin Cancer Res"},{"key":"3267_CR38","doi-asserted-by":"publisher","first-page":"76902","DOI":"10.18632\/oncotarget.12357","volume":"7","author":"J Feucht","year":"2016","unstructured":"Feucht J, Kayser S, Gorodezki D et al (2016) T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80\/CD86 on leukemic blasts. Oncotarget 7:76902\u201376919. https:\/\/doi.org\/10.18632\/oncotarget.12357","journal-title":"Oncotarget"},{"key":"3267_CR39","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/cas.13424","volume":"109","author":"K Mimura","year":"2018","unstructured":"Mimura K, Teh JL, Okayama H et al (2018) PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. Cancer Sci 109:43\u201353. https:\/\/doi.org\/10.1111\/cas.13424","journal-title":"Cancer Sci"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03267-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-022-03267-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03267-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T14:05:17Z","timestamp":1674482717000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-022-03267-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,13]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["3267"],"URL":"https:\/\/doi.org\/10.1007\/s00262-022-03267-5","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,13]]},"assertion":[{"value":"18 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Chen Li and Feng Guo have no potential conflicts of interest to disclose. All other authors are employees of Innovent Biologics. Innovent Biologics has filed patent applications of this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All authors agree to publish this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All mice experiments were performed in accordance with the regulations for care and use of laboratory animals at Innovent Biologics and were approved by the Institutional Animal Care and Use Committee. All monkey experiments were approved by IACUC and performed by WestChina-Frontier PharmaTech, according to the regulations of Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}